Secondary Logo

Institutional members access full text with Ovid®

Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society

Egawa, Shinichi MD, PhD, FACS*†; Toma, Hiroki MD, PhD*‡; Ohigashi, Hiroaki MD, PhD; Okusaka, Takuji MD, PhD*∥; Nakao, Akimasa MD, PhD, FACS; Hatori, Takashi MD*#; Maguchi, Hiroyuki MD, PhD***; Yanagisawa, Akio MD, PhD*††; Tanaka, Masao MD, PhD, FACS*‡

doi: 10.1097/MPA.0b013e318258055c
Original Articles
Buy

Objectives Since 1981, the Japan Pancreas Society has been hosting a nationwide pancreatic cancer registry. To commemorate its 30th anniversary, we review its history and latest achievement.

Methods During 3 decades, more than 350 leading institutions in Japan contributed voluntarily to register and periodic follow-up. The registry was modified to protect privacy by encrypting and hash algorithm.

Results From 1981 to 2007, 32,619 cumulative records were analyzed. The overall survival of invasive cancer was improved significantly. More patients with earlier stage or with intraductal and cystic neoplasms underwent resection. The strongest prognostic factor of Union for International Cancer Control (UICC) stage IIA and IIB tubular adenocarcinoma in the pancreatic head was histological grade, followed by tumor size, extent of lymph node dissection, and postoperative chemotherapy. The 5-year survival rate of Union for International Cancer Control stage 0 reached 85%. The improvement of survival of patients with invasive cancer in Japan can be attributed to the introduction of effective chemotherapies, regionalization, and the earlier diagnosis and treatment. Simple definition of “early pancreatic cancer” is needed.

Conclusions At the 30th year anniversary, the Japan Pancreas Society nationwide pancreatic cancer registry is more shining than ever for current perspectives and for future diagnostic and treatment tactics.

From the *Committee for Pancreatic Cancer Registry of Japan Pancreas Society, Fukuoka; †Division of Hepato-Biliary-Pancreatic Surgery, Tohoku University Graduate School of Medicine, Sendai; ‡Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka; §Department of Gastrointestinal Surgery, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka; ∥Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo; ¶Nagoya Central Hospital, Nagoya; #Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo; **Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo; and ††Department of Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Received for publication March 2, 2012; accepted March 29, 2012.

Reprints: Shinichi Egawa, MD, PhD, FACS, Division of Hepato-Biliary-Pancreatic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan (e-mail: egawas@surg1.med.tohoku.ac.jp).

The authors other than T Okusaka have no conflicts of interest or funding to disclose. T Okusaka has the following disclosures: Ely Lilly Japan K.K., Bayer Yakuhin, Ltd, Dainippon Sumitomo Pharma, Kowa Company, Ltd, Takeda Bio Development Center Ltd, AstraZeneca Co Ltd, Novartis Pharma K.K., Pfizer Japan Inc, Chugai Pharmaceutical Co Ltd, Ohtsuka Pharmaceutical Co Ltd, Eizai Co Ltd, Abbot Japan Co Ltd, Taiho Pharmaceutical Co Ltd, Onco Therapy Science Inc, Yakult Honsha Co Ltd, Shizuoka Sangyo, Bristol-Myers KK, Ajinomoto Pharma KK, Mylan Inc, Merck Serono. The details are listed in the Copyright Transfer Agreement form.

© 2012 Lippincott Williams & Wilkins, Inc.